Impaired functional responses in follicular lymphoma CD8+TIM-3+ T lymphocytes following TCR engagement

ABSTRACT Upregulation of T cell immunoglobulin-3 (TIM-3) has been associated with negative regulation of the immune response in chronic infection and cancer, including lymphoma. Here, we investigated the possible correlation between TIM-3 expression by ex vivo cytotoxic T cells (CTL) from follicular lymphoma (FL) biopsies and their functional unresponsiveness that could limit the favorable impact of CTL on disease progression. We report a high percentage of CD8+TIM-3+T cells in lymph nodes of FL patients. When compared to their CD8+TIM-3− counterparts, CD8+TIM-3+ T cells exhibited defective cytokine production following TCR engagement. Furthermore, CD8+TIM-3+ T cells display ex vivo markers of lytic granule release and remain unresponsive to further TCR-induced activation of the lytic machinery. Although confocal microscopy showed that TIM-3 expression on CD8+ T cells correlated with minor alterations of immunological synapse, a selective reduction of ERK signaling in CD8+TIM-3+T cells was observed by phospho-flow analysis. Finally, short relapse-free survival despite rituximab(R)-chemotherapy was observed in patients with high content of TIM-3+ cells and a poor infiltrate of granzyme B+ T cells in FL lymph nodes. Together, our data indicate that, besides selective TCR early signaling defects, TIM-3 expression correlates with unresponsiveness of ex vivo CD8+ T cells in FL. They show that scores based on the combination of exhaustion and cytolytic markers in FL microenvironment might be instrumental to identify patients at early risk of relapses following R-chemotherapy.

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  C. Baldari,et al.  Human Cytotoxic T Lymphocytes Form Dysfunctional Immune Synapses with B Cells Characterized by Non-Polarized Lytic Granule Release. , 2016, Cell reports.

[3]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[4]  D. Vignali,et al.  Inhibitory receptors as targets for cancer immunotherapy , 2015, European journal of immunology.

[5]  P. Brousset,et al.  Several immune escape patterns in non-Hodgkin's lymphomas , 2015, Oncoimmunology.

[6]  John T. Chang,et al.  Regulation of Asymmetric Division and CD8+ T Lymphocyte Fate Specification by Protein Kinase Cζ and Protein Kinase Cλ/ι , 2015, The Journal of Immunology.

[7]  M. Ostrowski,et al.  T Cell Ig and Mucin Domain–Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases , 2014, The Journal of Immunology.

[8]  J. Wolchok,et al.  Immune modulation in cancer with antibodies. , 2014, Annual review of medicine.

[9]  R. Davis,et al.  Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. , 2014, The Lancet. Oncology.

[10]  Pierre Brousset,et al.  Whole-slide imaging is a robust alternative to traditional fluorescent microscopy for fluorescence in situ hybridization imaging using break-apart DNA probes. , 2013, Human pathology.

[11]  S. Markovic,et al.  Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth , 2013, Oncoimmunology.

[12]  L. Dupré,et al.  An initial and rapid step of lytic granule secretion precedes microtubule organizing center polarization at the cytotoxic T lymphocyte/target cell synapse , 2013, Proceedings of the National Academy of Sciences.

[13]  X. Lu,et al.  Tim‐3/galectin‐9 signaling pathway mediates T‐cell dysfunction and predicts poor prognosis in patients with hepatitis B virus‐associated hepatocellular carcinoma , 2012, Hepatology.

[14]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[15]  T. Niki,et al.  IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. , 2012, The Journal of clinical investigation.

[16]  A. Anderson.  Tim-3, a negative regulator of anti-tumor immunity. , 2012, Current opinion in immunology.

[17]  B. Lu,et al.  TIM-3 Expression Characterizes Regulatory T Cells in Tumor Tissues and Is Associated with Lung Cancer Progression , 2012, PloS one.

[18]  P. Brousset,et al.  Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study. , 2011, Blood.

[19]  M. Smyth,et al.  Prospects for TIM3-Targeted Antitumor Immunotherapy. , 2011, Cancer research.

[20]  J. Kirkwood,et al.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.

[21]  Jenna M. Sullivan,et al.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity , 2010, The Journal of experimental medicine.

[22]  G. Freeman,et al.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection , 2010, Proceedings of the National Academy of Sciences.

[23]  S. Sehrawat,et al.  Galectin-9/TIM-3 Interaction Regulates Virus-Specific Primary and Memory CD8+ T Cell Response , 2010, PLoS pathogens.

[24]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[25]  Birgitta Sander,et al.  A Unifying Microenvironment Model in Follicular Lymphoma: Outcome Is Predicted by Programmed Death-1–Positive, Regulatory, Cytotoxic, and Helper T Cells and Macrophages , 2010, Clinical Cancer Research.

[26]  M. Calaminici,et al.  Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. , 2009, Blood.

[27]  B. McMahon,et al.  Negative Immune Regulator Tim-3 Is Overexpressed on T Cells in Hepatitis C Virus Infection and Its Blockade Rescues Dysfunctional CD4+ and CD8+ T Cells , 2009, Journal of Virology.

[28]  V. Kuchroo,et al.  The costimulatory role of TIM molecules , 2009, Immunological reviews.

[29]  E. Wherry,et al.  The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responses. , 2009, Current opinion in immunology.

[30]  Y. Liu,et al.  Blockade of Tim-3 Pathway Ameliorates Interferon-γ Production from Hepatic CD8+ T Cells in a Mouse Model of Hepatitis B Virus Infection , 2009, Cellular and Molecular Immunology.

[31]  J. Rossi,et al.  Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. , 2008, Blood.

[32]  R. Kaul,et al.  Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection , 2008, The Journal of experimental medicine.

[33]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[34]  B. Sander,et al.  CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma , 2007, Clinical Cancer Research.

[35]  Marylène Lejeune,et al.  Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Nolan,et al.  Kinetics of B Cell Receptor Signaling in Human B Cell Subsets Mapped by Phosphospecific Flow Cytometry1 , 2006, The Journal of Immunology.

[37]  H. Ostergaard,et al.  A Role for Phosphatidylinositol 3-Kinase in TCR-Stimulated ERK Activation Leading to Paxillin Phosphorylation and CTL Degranulation1 , 2005, The Journal of Immunology.

[38]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[39]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Marcus,et al.  CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.

[41]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[42]  R. Koup,et al.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. , 2003, Journal of immunological methods.

[43]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  F. Dumont,et al.  Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. , 1998, Journal of immunology.

[45]  A. Lanzavecchia,et al.  Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy , 1996, The Journal of experimental medicine.